Nisa Investment Advisors LLC Sells 50,268 Shares of Catalent, Inc. (NYSE:CTLT)

Nisa Investment Advisors LLC cut its position in Catalent, Inc. (NYSE:CTLT - Free Report) by 87.3% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 7,280 shares of the company's stock after selling 50,268 shares during the quarter. Nisa Investment Advisors LLC's holdings in Catalent were worth $327,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Gladius Capital Management LP acquired a new position in Catalent in the 3rd quarter valued at $28,000. KB Financial Partners LLC bought a new stake in Catalent in the 1st quarter valued at $30,000. Exchange Traded Concepts LLC bought a new stake in Catalent in the 3rd quarter valued at $31,000. Cary Street Partners Investment Advisory LLC boosted its holdings in Catalent by 1,162.3% in the 3rd quarter. Cary Street Partners Investment Advisory LLC now owns 770 shares of the company's stock valued at $35,000 after purchasing an additional 709 shares during the period. Finally, Jefferies Financial Group Inc. bought a new stake in Catalent in the 4th quarter valued at $61,000.

Catalent Price Performance

CTLT traded down $0.32 during midday trading on Friday, hitting $55.48. The company had a trading volume of 1,588,131 shares, compared to its average volume of 2,579,957. The company has a debt-to-equity ratio of 1.34, a quick ratio of 1.73 and a current ratio of 2.48. The company has a market capitalization of $10.04 billion, a PE ratio of -8.16, a P/E/G ratio of 6.04 and a beta of 1.20. Catalent, Inc. has a twelve month low of $31.45 and a twelve month high of $60.20. The firm's 50-day simple moving average is $56.81 and its 200-day simple moving average is $48.24.

Catalent (NYSE:CTLT - Get Free Report) last posted its quarterly earnings data on Friday, February 9th. The company reported ($0.24) earnings per share for the quarter, missing the consensus estimate of ($0.02) by ($0.22). Catalent had a negative net margin of 29.91% and a negative return on equity of 2.43%. The company had revenue of $1.03 billion during the quarter, compared to analyst estimates of $1.01 billion. During the same quarter in the previous year, the business posted $0.62 EPS. The company's revenue was down 10.2% compared to the same quarter last year. Equities research analysts predict that Catalent, Inc. will post 0.28 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of analysts have weighed in on the stock. StockNews.com assumed coverage on shares of Catalent in a report on Friday. They issued a "sell" rating for the company. Royal Bank of Canada reaffirmed a "sector perform" rating and set a $63.50 price objective on shares of Catalent in a report on Tuesday, February 20th. UBS Group reaffirmed a "neutral" rating and set a $63.50 price objective (up from $58.00) on shares of Catalent in a report on Tuesday, February 6th. Stephens reissued an "equal weight" rating and set a $63.50 price target on shares of Catalent in a report on Thursday, April 4th. Finally, Barclays lifted their price target on shares of Catalent from $45.00 to $47.00 and gave the company an "equal weight" rating in a report on Thursday, January 25th. Two research analysts have rated the stock with a sell rating, nine have issued a hold rating and three have given a buy rating to the company's stock. Based on data from MarketBeat.com, the company currently has a consensus rating of "Hold" and an average price target of $52.46.

Catalent Profile

Catalent, Inc, together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. It operates in two segments, Biologics, and Pharma and Consumer Health. The Biologics segment provides formulation, development, and manufacturing for biologic proteins, cell gene, and other nucleic acid therapies; pDNA, iPSCs, oncolytic viruses, and vaccines; formulation, development, and manufacturing for parenteral dose forms, including vials, prefilled syringes, and cartridges; and analytical development and testing services for large molecules.